Injection   sessions   must  be   conducted  observing   Good   Medical   Practice   (G M P).

All injection procedures have contamination risk factors; observe Body Substance isolation  (BSI)  precautions  and  strict  aseptic  methods  to  prevent  infection  and / or  contagion  associated with injectable materials.

 Routinely   clean   and   disinfect   equipment   and   furnishings   in   patient  care  areas.

 Observe Universal Precautions (UP) when handling syringes and needles to avoid   injury  and  contamination  during  activation  and  application  of  Derma  Veil.

 Handle  and  dispose  of used vials, syringes and needles with Universal Precautions  (UP) guidelines and  applicable  local  government  regulations; avoid recapping used   needles, avoid removing used needles  from  disposable  syringes,  avoid  bending, or manipulating used needles by hand. Place used sharps in puncture-resistant containers.

The  use  of  Derma Veil   in  combination  with other fillers and/or muscle  inhibitors   (i.e., Botulinum toxin) during the same treatment session has not been  studied  or  evaluated     and should be avoided.

There is an  increased  risk of bleeding and hematoma formation at the injection  site  for  patients  taking  blood  thinning  medications  (anti  coagulant  therapy) or  who  have  a coagulation deficiency.

Suspend  the use  of  aspirin  based  products  5  days before the start of the treatment.   

 If  a  treatment based on an active dermal response (i.e., laser, mechanical or  chemical peeling,  UV  irradiation)  is considered prior to, or  after the  application   of  Derma Veil,     there is the risk of causing an inflammatory reaction in the area where   Derma Veil   was  implanted.  For  such  treatments  a  minimum  of  30  days  is   recommended before  or     after the last application of Derma Veil.

The patient  should  be  informed to limit sun exposure of the treated area and not  to use   UV lamp systems for  48 hours  following  the  application of Derma Veil or until any swelling and/or redness has totally subsided.

 It has  not  been  determined if Derma Veil is radiopaque. The asymmetric micro  particles     of the  compound  may  be  visible  on scans, ultrasound, standard radiography, magneti resonance  imaging  (MRI), or  computer tomography (CT). Patients should know that the device  may  be  radiopaque and inform their treating physician,  specialist,  radiologist  or  healthcare  professional  of the presence of Derma Veil.